Xu Kemin, Lu Yanjun
School of Laboratory Medicine, Hubei University of Chinese Medicine, Hubei Shizhen Laboratory Wuhan, Hubei, P. R. China.
Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, Hubei, P. R. China.
Int J Clin Exp Pathol. 2025 Jul 15;18(7):287-301. doi: 10.62347/FXIN5300. eCollection 2025.
Liver hepatocellular carcinoma (LIHC) is the most prevalent liver malignancy, often diagnosed at advanced stages, and resulting in a poor prognosis for patients. Ubiquitin-specific peptidase 22 (USP22) belongs to the ubiquitin-specific processing proteases (USPs) subfamily and has been identified as a gene signature associated with various cancer types in previous studies. However, the exact role of USP22 in LIHC remains to be fully elucidated.
Multiple online bioinformatics databases were usedto investigate gene expression patterns, prognosis, mutations, and immune infiltration in LIHC patients. The UALCAN database was employed to analyze the gene expression of USP22 and its correlation with clinicopathologic data. The cBioPortal database was used to analyze the mutation status, and the Human Protein Atlas (HPA) database was utilized to illustrate the protein's localization. The STRING and GeneMANIA databases were employed to establish the protein-protein interaction (PPI) network. The GEPIA2 database was used to identify the top 100 genes correlated with USP22 in LIHC, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using the 'clusterProfiler' R package. The TISIDB database was used to analyze the correlation between the USP22 gene and immune infiltration in LIHC.
USP22 was upregulated in LIHC, with high levels of USP22 correlating with poor overall survival (OS) (P=0.019) and showing associations with tumor stage, histologic subtype, and TP53 mutant status. Immunohistochemistry data showed that USP22 localized in the nucleus of hepatocytes. Nine proteins, including ATXN7, ENY2, TRRAP, TAF5L, TADA3, TADA1, SUPT3H, SUPT20H, and ATXN7L3, were identified as the hub binding proteins in PPI networks. GO and KEGG enrichment analyses indicated that the genes correlated with USP22 in HCC were involved in histone modification, RNA splicing, and regulation of mRNA metabolic processes and were associated with the Notch signaling pathway, ubiquitin-mediated proteolysis, and the Wnt signaling pathway. Moreover, USP22 expression exhibited a significant negative correlation with immune infiltration by CD8+ T cells, macrophages, monocytes, and NK cells.
The prognostic relevance of USP22 in LIHC was found by leveraging data from multiple databases, providing fresh insight that targeting USP22 may help develop new therapeutic approaches for LIHC.
肝细胞肝癌(LIHC)是最常见的肝脏恶性肿瘤,常于晚期被诊断出来,导致患者预后不良。泛素特异性蛋白酶22(USP22)属于泛素特异性加工蛋白酶(USPs)亚家族,在先前的研究中已被确定为与多种癌症类型相关的基因特征。然而,USP22在LIHC中的确切作用仍有待充分阐明。
使用多个在线生物信息学数据库来研究LIHC患者的基因表达模式、预后、突变和免疫浸润情况。利用UALCAN数据库分析USP22的基因表达及其与临床病理数据的相关性。使用cBioPortal数据库分析突变状态,并利用人类蛋白质图谱(HPA)数据库说明该蛋白的定位。运用STRING和GeneMANIA数据库建立蛋白质-蛋白质相互作用(PPI)网络。使用GEPIA2数据库鉴定LIHC中与USP22相关的前100个基因,并使用“clusterProfiler”R包进行基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析。使用TISIDB数据库分析USP22基因与LIHC中免疫浸润的相关性。
USP22在LIHC中上调,高水平的USP22与总体生存期(OS)较差相关(P = 0.019),并与肿瘤分期、组织学亚型和TP53突变状态有关。免疫组化数据显示USP22定位于肝细胞的细胞核中。包括ATXN7、ENY2、TRRAP、TAF5L、TADA3、TADA1、SUPT3H、SUPT20H和ATXN7L3在内的9种蛋白质被确定为PPI网络中的核心结合蛋白。GO和KEGG富集分析表明,HCC中与USP22相关的基因参与组蛋白修饰、RNA剪接以及mRNA代谢过程的调控,并与Notch信号通路、泛素介导的蛋白水解和Wnt信号通路相关。此外,USP22表达与CD8 + T细胞、巨噬细胞、单核细胞和NK细胞的免疫浸润呈显著负相关。
通过利用多个数据库的数据发现了USP22在LIHC中的预后相关性,为靶向USP22可能有助于开发LIHC的新治疗方法提供了新见解。